Adial Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)
Adial Pharmaceuticals, Inc. (ADIL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) of $197.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss · last filed 2022-11-14
- Adial Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-09-30 was $75.00K.
- Adial Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-06-30 was -$24.00K.
- Adial Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-03-31 was $146.00K, a 2226.69% increase year-over-year.
- Adial Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2021-12-31 was $54.01K.
- Adial Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2021 was -$281.71K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month |
|---|---|---|---|---|
| 2022-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $51.00K derived: sum of 2 quarters · filed 2022-11-14 | $197.00K 10-Q · filed 2022-11-14 | $251.01K derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $122.00K 10-Q · filed 2022-08-15 | $176.01K derived: sum of 3 quarters · filed 2022-08-15 | -$98.51K derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | $146.00K 10-Q · filed 2022-05-16 | $200.01K derived: sum of 2 quarters · filed 2022-05-16 | -$74.51K derived: sum of 3 quarters · filed 2022-05-16 | -$141.99K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | $54.01K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$220.51K derived: sum of 2 quarters · filed 2022-03-28 | -$287.99K derived: sum of 3 quarters · filed 2022-03-28 | -$281.71K 10-K · filed 2022-03-28 |
| 2021-09-30 | -$274.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$342.00K derived: sum of 2 quarters · filed 2021-11-15 | -$335.73K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$67.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$61.20K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $6.28K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |